About Upstream stimulatory factor 2
Upstream stimulatory factor 2 (USF2) is a protein
from Homo sapiens identified by UniProt accession
Q15853, 346 residues long.
MolForge cross-references it against 0 known binders and
90 disease associations.
Target properties
| Protein name | Upstream stimulatory factor 2 |
|---|
| UniProt accession | Q15853 |
|---|
| Gene | USF2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 346 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (90)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.54
- Red cell distribution width · score 0.19
- mean corpuscular volume · score 0.18
- mean corpuscular hemoglobin · score 0.17
- mean corpuscular hemoglobin concentration · score 0.15
- erythrocyte count · score 0.14
- red blood cell density measurement · score 0.11
- prostate carcinoma · score 0.11
- prostate cancer · score 0.11
- Familial prostate cancer · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q15853-F1 | alphafold | PREDICTED | 58.46 | — |
Amino-acid sequence (346 residues)
MDMLDPGLDP AASATAAAAA SHDKGPEAEE GVELQEGGDG PGAEEQTAVA ITSVQQAAFG DHNIQYQFRT ETNGGQVTYR VVQVTDGQLD GQGDTAGAVS VVSTAAFAGG QQAVTQVGVD GAAQRPGPAA ASVPPGPAAP FPLAVIQNPF SNGGSPAAEA VSGEARFAYF PASSVGDTTA VSVQTTDQSL QAGGQFYVMM TPQDVLQTGT QRTIAPRTHP YSPKIDGTRT PRDERRRAQH NEVERRRRDK INNWIVQLSK IIPDCNADNS KTGASKGGIL SKACDYIREL RQTNQRMQET FKEAERLQMD NELLRQQIEE LKNENALLRA QLQQHNLEMV GEGTRQ
Explore Upstream stimulatory factor 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets